Had they continued to approve other drugs based on lipid effects after they lost faith in surrogate outcomes in this space then I would agree with you.
Until you've run a big outcomes RCT you don't really know the trade of safety vs efficacy. I'll make the wager that some kind of p<0.1 safety signal pops up (although it may take 5 years before it is acknowledged - because that is the nature of these things. Eg almost 20 years to acknowledge statins cause increase in T2D)